Abstract:Background For ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) patients, tumor necrosis factor (TNF) inhibitors are recommended when disease activity persists despite non-steroidal anti-inflammatory drugs. Objectives To evaluate the efficacy and safety of TNF inhibitors in patients with AS and nr-axSpA. Methods Searching PubMed, Embase, Cochrane Library, CNKI and WanFang databases, we included all double-blind randomized controlled trials (RCTs) that compared a TNF inhibitor with placebo in AS/nr-axSpA patients. The efficacy endpoints included the proportions of patients reaching Assessment in Ankylosing Spondylitis 20% response (ASAS20), ASAS5/6, partial remission, and Bath Ankylosing Spondylitis Disease Activity Index 50% improvement (BASDAI50). We used adverse events (AEs), withdrawals due to AEs and severe AEs to evaluate the safety of biologics. TNF inhibitors were pooled to perform comparison with placebo and among themselves, calculating odds ratios (OR) with associated 95% credible intervals (CrI), probability of being best (Pbest) and the surface under the cumulative ranking curve (SUCRA) as well as numbers needed to treat (NNT). Results Twenty-nine double-blind RCTs with 5200 patients were included in the analysis focusing on 6 TNF inhibitors, including etanercept, intended copies of etanercept, adalimumab, infliximab, golimumab and certolizumab. Compared with placebo, TNF inhibitors were efficacious in achieving ASAS20, ASAS5/6, partial remission and BASDAI50 responses, but with an increased risk of AEs and withdrawals due to AEs. No significant differences in efficacy were found among biologics, except that etanercept had a higher rate of ASAS20 response compared with golimumab in the Chinese patients (OR 4.78, 95% CrI 1.20–17.84). Among the Chinese population, etanercept was ranked the most efficacious therapy for ASAS20 with NNT of 2 (Pbest 93.6%, SUCRA 0.97). Conclusions Compared to placebo, TNF inhibitors are efficacious in controlling disease activity for AS and nr-axSpA patients without a higher risk of severe AEs. Although no significant differences in efficacy among biologics were found, the Chinese population had a better ASAS20 response to etanercept. References Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis care & research 2015. Rudwaleit M, Haibel H, Baraliakos X, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis and rheumatism 2009;60:717–27. Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. The Cochrane database of systematic reviews 2015;4:Cd005468. Callhoff J, Sieper J, Weiss A, et al. Efficacy of TNFalpha blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Annals of the rheumatic diseases 2015;74:1241–8. Disclosure of Interest None declared

Study of thyroid disorders in ankylosing spondylitis patients on anti-tumor necrosis factor treatment

Thyroid involvement in ankylosing spondylitis and relationship of thyroid dysfunction with anti-TNF α treatment

Efficacy and safety of TNF-α inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis

Vitamin D in Ankylosing Spondylitis: Review and Meta-Analysis

Autoimmune thyroid disease in ankylosing spondylitis

A Clinical Study of Thyroid Abnormalities and Autoantibodies in Patients Diagnosed With Anti-nuclear Antibody Positive Autoimmune Connective Tissue Disorders: An Observational Cross-Sectional Study

Levels of Circulating Th17 Cells and Regulatory T Cells in Ankylosing Spondylitis Patients with an Inadequate Response to Anti−TNF-α Therapy

Clinical Observation on Recombinant Human TypeⅡTumor Necrosis Factor Receptor-antibody Fusion Protein and Immunosuppressive Agents in Treatment of Patients with Ankylosing Spondylitis

Concurrent Intervention with Exercises and Stabilized Tumor Necrosis Factor Inhibitor Therapy Reduced the Disease Activity in Patients with Ankylosing Spondylitis

Clinical Effect of Recombinant Human Type Ⅱ Tumor Necrosis Factorreceptor-Antibody Fusion Protein in Treatment of Ankylosing Spondylitis

Adverse Events of Anti-Tumor Necrosis Factor Α Therapy in Ankylosing Spondylitis

Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry

Comparative Efficacy of Advanced Therapies in the Treatment of Radiographic Axial Spondyloarthritis or Ankylosing Spondylitis as Evaluated by the ASDAS Low Disease Activity Criteria

Pain and Fatigue in Patients With Ankylosing Spondylitis Treated With Tumor Necrosis Factor Inhibitors: Multinational Real-World Findings

AB0662 Indirect Comparison of TNF Inhibitors for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials

Thyroid involvement in chronic inflammatory rheumatological disorders

Effect of anti-tumor necrosis factor therapy on the efficacy of aerobic exercise in patients with ankylosing spondylitis

Serum sCTLA-4 levels and clinical manifestations in ankylosing spondylitis patients

Decreased Serotonin Levels and Serotonin-Mediated Osteoblastic Inhibitory Signaling in Patients With Ankylosing Spondylitis

Role of Th1/Th2 Cytokines in the Diagnosis and Prognostic Evaluation of Ankylosing Spondylitis.

"Long-term MRI findings in Ankylosing spondylitis patients treated with TNF inhibitors for a decade"